A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
But the former is paying a fraction of what Merck shelled out for raludotatug.
INCA033989 looks potent in essential thrombocythemia, but already the opportunity looks tiny.
The Enliven molecule looks competitive against Scemblix, triggering a $200m raise.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
